How to Buy Xeris Biopharma Holdings Stock
Xeris Biopharma Holdings Inc
Xeris Biopharma Holdings, Inc. , a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology.
Xeris Biopharma Holdings stock last closed at $4.35, down 1.58% from the previous day, and has increased 95.95% in one year. It has overperformed other stocks in the Biotechnology industry by 1.72 percentage points. Xeris Biopharma Holdings stock is currently +114.29% from its 52-week low of $2.03, and -28.34% from its 52-week high of $6.07.
At the moment, there are 160.16M shares of XERS outstanding. The market capitalization of XERS is $696.67M. In the last 24 hours, 1.78M XERS shares were traded.
How to Buy Xeris Biopharma Holdings Stock
Not sure how to invest in Xeris Biopharma Holdings stock? Here's how.
- Choose where to buy Xeris Biopharma Holdings stock: You need to decide on an online brokerage, but don't worry - we've sifted through dozens of online stock brokerages and apps to help you choose where to buy Xeris Biopharma Holdings stock.
- Create a brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've found.
- Deposit funds into your investment account: Choose your method of payment and add your details.
- Research Xeris Biopharma Holdings stock: The Xeris Biopharma Holdings ticker symbol is XERS. Is Xeris Biopharma Holdings stock a good investment? Should you buy shares of XERS? How do XERS's underlying business fundamentals look? Do top analysts think Xeris Biopharma Holdings is a good buy? Why has XERS's stock price moved recently? (Hint: Our stock market research tools can help you figure out if XERS is a good stock to buy).
- Place your XERS trade: Decide if you will purchase XERS shares at the current market price or use a limit order to purchase XERS stock at a given price.
- Get notifications regarding your XERS investment: Create a watchlist to watch your new investment in Xeris Biopharma Holdings stock.
Step 1: Choose where to buy Xeris Biopharma Holdings stock
You need a brokerage account to access the NASDAQ market and buy XERS stock.
Our favorite brokerage: eToro
We believe that eToro is the best stock brokerage. Here's why:
- You can invest in stocks with zero commissions: Invest without commissions.
- Buy fractional shares: Even if you can't afford a full share, you can still purchase the stock.
- Access to global markets: From Tech to Energy, New York to Hong Kong (for US users, only US stocks are available) — you can fill your portfolio with stocks from the globe's top exchanges.
- Social investing: eToro offers a community with more than 20 million users worldwide. Talk to, learn from, and copy the unique crypto portfolios of other investors.
- Security: eToro is a regulated and licensed brokerage platform.
- Buy other assets: Such as ETFs and cryptocurrencies.
Get $10 towards your purchase of shares by opening an account with eToro today. This offer is only for US users.
Open eToro AccountStep 2: Create a brokerage account
Now that you've chosen your brokerage, you'll need to fill out some personal details so you are able to buy XERS today.
How to Open a New Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Input your personal details to start your new trading account.
- Send your data by pressing the "Create Account" button. Get started with eToro today
Step 3: Deposit funds into your investment account
Now that you have opened your account on a good stock buying app, you need to deposit funds:
Watch this video walkthrough for more details depositing funds into your brokerage account.
Step 4: Research Xeris Biopharma Holdings stock
After you have chosen the best place to buy Xeris Biopharma Holdings stock, it's absolutely critical to analyze their stock before you invest, so you can understand the risk and opportunity.
Xeris Biopharma Holdings shares data
Fundamentals of Xeris Biopharma Holdings
WallStreetZen was designed to help everyday investors perform more in-depth fundamental analysis in minutes instead of hours.
You can view all of the due diligence checks on XERS's stock page.
Is XERS stock properly valued?
You can use many financial metrics, analyses, models, and charts to gauge XERS's intrinsic value.
You can access more valuation analysis on XERS's stock here.
XERS Financials at a glance
Positive Financial Indicators:
- XERS profit margin has gone up from -37.6% to -20.3% in the past year.
- There are more short-term assets than short-term liabilities on the XERS balance sheet.
- XERS has cash burn of 27426000. It has enough cash and short-term investments to cover this for at least one year.
- XERS has $58.44M in cash and short term investments. This is sufficient to cover its annual cash burn of $27.43M.
Negative Financial Indicators:
- There are more long-term liabilities than short-term assets on the XERS balance sheet.
- Total XERS debt is still negative.
- XERS debt to equity ratio of -9.98 is negative.
Do analysts think it's a good time to buy XERS stock
Out of 6 sell side analysts who monitor XERS, the consensus analyst rating on Xeris Biopharma Holdings is a Buy
It's important to note that analyst ratings are not stock recommendations, nor are they investment advice.
Most Recent XERS Analyst Recommendations
Glen Santangelo, a top 34% analyst from Jefferies reiterates XERS with a strong buy rating and raises their XERS price target from $4.00 to $6.00, on Jan 29, 2025.
You can dig deeper into what analysts are saying on the Xeris Biopharma Holdings stock forecast page.
XERS Trading Indicators
How are XERS Revenues/Earnings doing?
Last year, XERS revenue was $222.55M. During the past five year, XERS's revenue has grown by 120.58% per year. This was faster than the Biotechnology industry average of 43.24%.
Dig into XERS's earnings and revenue performance here.
Are XERS executives and large shareholders buying or selling the stock?
In the last 12 months, insiders at XERS have sold more shares than they have bought.
Kevin McCulloch, President and Chief Operating Officer of XERS, was the latest XERS insider to sell. They sold $3,774.95 worth of XERS shares on Apr 2, 2025.
Get more info about who owns XERS stock here.
Can I rely on XERS as an income stream?
No, Xeris Biopharma Holdings doesn't provide an income stream by paying out dividends.
Get analysis from other investors
One of the reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to find out what other community members have to say.
Step 5: Place your XERS trade
There are two primary order types:
- Market order: A market order is an order to buy or sell a stock at the best price on the market.
Market orders are usually the easiest way to buy. - Limit order: A limit order allows you to buy or sell a stock at a specific price (or better).
If you want to be sure you're buying or selling at a specific price, use a limit order.
Click the Open button and your broker will place the order.
If you require more info about investing in stocks on eToro, watch the how to video below:
Step 6: Get notifications regarding your XERS investment
Now that you own some XERS shares, you'll want to keep up with your stock purchase.
Create a watchlist to get notified of the latest news about your XERS stock.
XERS Feed
How to Buy Stock in Xeris Biopharma Holdings
To summarize, here are the 6 steps for buying Xeris Biopharma Holdings stock:
- Choose where to buy Xeris Biopharma Holdings stock
- Create a brokerage account
- Deposit funds into your investment account
- Research Xeris Biopharma Holdings stock
- Place your XERS trade
- Get notifications regarding your XERS investment
If you need a brokerage account, eToro is our recommended option.
Get Started with eToro TodayIf you want to keep track of your new investment in Xeris Biopharma Holdings, click the button below.
Trending Stock Buying Guides
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.